Table 2.
90-day outcomes by baseline neurological severity
| Outcome* | Lying flat versus sitting up | OR (95% CI) | P value | aOR (95% CI) | P value |
| NIHSS <7 | |||||
| Ordinal mRS | 1.07 (0.83 to 1.37) | 0.62 | 1.03 (0.80 to 1.33) | 0.73 | |
| Binary mRS 3–6 | 26.6% versus 26.2% | 1.02 (0.72 to 1.45) | 0.89 | 0.93 (0.63 to 1.37) | 0.70 |
| Death | 3.9% versus 3.2% | 1.31 (0.65 to 2.66) | 0.46 | Did not converge† | |
| Cardiovascular SAEs* | 7.3% versus 7.2% | 1.03 (0.62 to 1.72) | 0.90 | 1.05 (0.62 to 1.78) | 0.85 |
| NIHSS≥7 | |||||
| Ordinal mRS | 0.94 (0.71 to 1.26) | 0.69 | 0.92 (0.67 to 1.25)‡ | 0.59 | |
| Binary mRS 3–6 | 58.7% versus 62.2% | 0.86 (0.67 to 1.15) | 0.31 | 0.74 (0.52 to 1.04) | 0.08 |
| Death | 13.6% versus 15.4% | 0.91 (0.59 to 1.41) | 0.67 | 0.80 (0.51 to 1.27) | 0.34 |
| Cardiovascular SAEs* | 16.0% versus 12.2% | 1.31 (0.87 to 1.99) | 0.20 | 1.21 (0.79 to 1.86) | 0.37 |
| NIHSS ≥10 | |||||
| Ordinal mRS | 0.87 (0.64 to 1.19) | 0.38 | 0.80 (0.58 to 1.10) | 0.16 | |
| Binary mRS 3–6 | 68.1% versus 69.6% | 0.89 (0.61 to 1.30) | 0.55 | 0.77 (0.49 to 1.19) | 0.24 |
| Death | 17.2% versus 20.5% | 0.85 (0.52 to 1.38) | 0.50 | 0.76 (0.46 to 1.24) | 0.27 |
| Cardiovascular SAEs* | 17.9% versus 15.4% | 1.16 (0.73 to 1.83) | 0.54 | 1.06 (0.66 to 1.70) | 0.81 |
| NIHSS ≥14 | |||||
| Ordinal mRS | 0.83 (0.56 to 1.27) | 0.36 | 0.82 (0.54 to 1.24) | 0.34 | |
| Binary mRS 3–6 | 77.3% versus 75.0% | 1.13 (0.65 to 1.98) | 0.66 | 1.05 (0.54 to 2.01) | 0.89 |
| Death | 22.8% versus 27.8% | 0.70 (0.42 to 1.19) | 0.19 | 0.72 (0.40 to 1.30) | 0.28 |
| Cardiovascular SAEs* | 23.5% versus 18.1% | 1.29 (0.75 to 2.21) | 0.36 | 1.30 (0.73 to 2.31) | 0.38 |
Adjusted OR (aOR) obtained for further adjusted age, sex, region groups, premorbid grade (0–1 vs 2–5) according to modified Rankin scale (mRS) assessed at baseline, comorbidity of heart disease, stroke or diabetes mellitus and National Institutes of Health Stroke Scale (NIHSS) at baseline as continuous variable.
*Cardiovascular serious adverse events (SAEs) include cerebrovascular events, cardiac events or other vascular events.
†Hierarchical model cannot be converge due to very few cases of death in this subgroup.
‡Hierarchical model only adjusted study design, age, sex, region groups, premorbid grade (0–1 vs 2–5) according to mRS assessed at baseline and comorbidity of heart disease, stroke or diabetes mellitus.